Can Chemo Cause Cataracts? Symptoms and Treatment

Chemotherapy can contribute to cataract formation, though the risk depends heavily on which drugs are used, how long treatment lasts, and whether radiation or corticosteroids are part of the regimen. Certain agents like busulfan and cytosine arabinoside have been directly linked to lens changes, and the steroid medications often given alongside chemo to control nausea can independently cloud the lens. The connection is well-documented enough that eye screening during and after cancer treatment is a real clinical concern, yet many patients are never told about it.

Which Chemotherapy Drugs Are Linked to Cataracts

Not every chemotherapy drug carries the same risk to the eyes. The strongest associations come from a handful of specific agents. Busulfan, an alkylating agent used primarily for leukemia and as part of bone marrow transplant conditioning, is one of the most clearly implicated. A case report documented a 42-year-old woman who developed posterior subcapsular cataracts in both eyes after receiving high doses of busulfan for just four days, well before the kind of prolonged exposure that had previously been thought necessary.¹

A large study of childhood and adolescent cancer survivors found that two other chemotherapy drugs were independently associated with cataracts after accounting for radiation dose to the lens. Cytosine arabinoside and doxorubicin each raised the odds of developing cataracts by about 50 percent compared to survivors who had not received those drugs.² That finding matters because doxorubicin is one of the most widely used chemotherapy agents across many cancer types, meaning a significant number of patients are exposed to a drug with a documented lens effect.

Other chemotherapy-related ocular side effects have been reported more broadly. A review of ocular complications noted that photophobia, cataracts, glaucoma, and retinopathy have all been documented following chemotherapy administration.³ So cataracts are part of a broader pattern of eye toxicity, not an isolated phenomenon.

The Steroid Problem That Gets Overlooked

Here is where the picture gets complicated in a way that surprises many patients. Corticosteroids like dexamethasone (brand name Decadron) are a routine part of chemotherapy regimens, prescribed to prevent nausea and vomiting and to reduce inflammation. These steroids are themselves a well-known cause of posterior subcapsular cataracts. When someone develops cataracts during or after chemo, it can be genuinely difficult to determine whether the chemotherapy drug, the corticosteroid, or the combination is responsible.

One early case report described a young patient who developed bilateral posterior subcapsular cataracts after only four courses of intermittent dexamethasone used as part of an antiemetic regimen for cisplatin-based chemotherapy. The cataracts were attributed to the dexamethasone, not the cisplatin itself, and the authors noted that this complication appeared far sooner than expected from typical steroid use, which usually takes years of chronic administration to cause lens changes.⁴

A large Korean population-based study of cancer survivors put some numbers on this. Among patients with blood cancers, short-term steroid use of less than six months did not significantly raise the risk of needing cataract surgery. But prolonged steroid use of six months or more nearly doubled the risk.⁵ The takeaway is that it often isn’t the chemo alone. The steroids that accompany it, especially when used for extended periods, are a major and sometimes dominant contributor.

Blood Cancers, Bone Marrow Transplants, and Elevated Risk

The risk of chemotherapy-related cataracts is not evenly distributed across cancer types. Patients with blood cancers carry a notably higher risk than those with solid tumors. In the Korean study, the hematologic cancer group had about a 60 percent higher risk of needing cataract surgery compared to matched controls without cancer, and this elevated risk persisted for at least five years after diagnosis.⁵ Among specific blood cancer types, leukemia patients had a 50 percent higher risk of cataract surgery.

Bone marrow transplant recipients face the steepest climb. The same study found that a history of bone marrow transplantation more than doubled the risk of eventually needing cataract surgery.⁵ This makes sense when you consider what transplant conditioning involves: high-dose chemotherapy (often busulfan or cyclophosphamide), sometimes total body irradiation, and extended courses of immunosuppressive steroids to prevent graft-versus-host disease. Each of those elements independently threatens the lens, and together they compound the effect substantially.

Patients with solid tumors, by contrast, showed a more modest and sometimes non-significant elevation in cataract risk. Their chemotherapy regimens tend to be shorter, involve fewer of the highest-risk drugs, and require less prolonged steroid exposure. That doesn’t mean their eyes are safe, but the risk profile is meaningfully different.

Why Children and Young Adults Are Especially Vulnerable

Childhood cancer survivors deserve their own discussion because their lenses are more susceptible and their post-treatment follow-up horizon stretches decades longer. The Childhood Cancer Survivor Study, which tracked thousands of survivors treated before the age of 21, found elevated cataract rates tied to both radiation and specific chemotherapy agents. Survivors treated with prednisone had roughly 2.3 times the risk of reporting cataracts compared to those who did not receive it.⁶

The developing lens in a child is more metabolically active and more sensitive to toxic insult than the fully mature adult lens. A cataract that forms in a five-year-old treated for leukemia may not become visually significant until their twenties or thirties, creating a delayed-onset problem that falls outside the typical surveillance window of pediatric oncology follow-up. Many childhood cancer survivors age out of their oncology clinics without being connected to an ophthalmologist who knows their treatment history.

The separate analysis of childhood survivors also confirmed that cytosine arabinoside and doxorubicin each independently raised cataract odds by about 50 percent even after adjusting for radiation dose to the lens.² That adjustment matters, because it means the drugs themselves are contributing, not just incidental radiation exposure.

What the Symptoms Feel Like

Chemotherapy-related cataracts tend to be posterior subcapsular cataracts, meaning the clouding starts at the back surface of the lens. This type has a distinct symptom profile that differs from the age-related nuclear cataracts most people picture when they hear the word.

Posterior subcapsular cataracts tend to cause:

Glare sensitivity: Bright lights, headlights at night, and sunlight become uncomfortably dazzling. This is often the first symptom people notice.
Near vision trouble: Reading and close-up work may deteriorate before distance vision does, which feels counterintuitive to patients who assume cataracts affect seeing far away.
Blurred or hazy vision: Things look foggy or washed out, and increasing your glasses prescription doesn’t fix it.
Rapid progression: Unlike age-related cataracts that typically develop over years, steroid-induced and some drug-related cataracts can progress over months.

Posterior subcapsular cataracts also have a distinctive optical quirk: they cause worse vision in bright light rather than dim light. In dim conditions, your pupil dilates and light passes around the opacity at the back of the lens. In bright light, your pupil constricts and funnels light right through the clouded area. So if you find your vision is paradoxically better in a dim restaurant than outside on a sunny day, that pattern is worth mentioning to your eye doctor.

Some patients dismiss early symptoms as normal aging or assume they’re related to fatigue from treatment. The case reports consistently describe patients presenting with “decreased visual acuity and blurred vision” that they initially attributed to other causes before the cataract was identified on exam.¹

When to Get Your Eyes Checked

There is no universally adopted screening protocol for chemo-related cataracts the way there is for, say, retinal screening in diabetes. But the clinical consensus leans toward baseline eye exams before starting high-risk regimens and periodic follow-up during and after treatment. A recent review of ocular side effects from targeted cancer therapies argued for pragmatic, evidence-based screening strategies tailored to specific treatments, calling on oncologists and trial designers to build appropriate ophthalmic monitoring into care protocols.⁷

In practice, if you are receiving or have received any of the higher-risk agents discussed above, or if your regimen included months of corticosteroids, a comprehensive dilated eye exam is worth requesting even if your oncologist hasn’t mentioned it. Bone marrow transplant recipients should be particularly proactive. The elevated cataract risk in that group persists for at least five years after transplant, and annual or biannual eye exams during that window can catch lens changes before they significantly impair vision.⁵

How Cataracts in Cancer Patients Are Treated

The good news is that chemotherapy-related cataracts are treated with the same surgery used for any other cataract: the clouded lens is removed and replaced with an artificial intraocular lens. The surgery is one of the most commonly performed and well-studied operations in all of medicine, with high success rates and a short recovery period. Visual impairment from cataracts carries real quality-of-life consequences for anyone, and cancer patients deserve the same access to surgical correction as the general population.⁸

There are, however, a few considerations specific to cancer patients that make the decision slightly more nuanced:

Timing relative to treatment: If you’re actively receiving chemotherapy, surgery may need to be scheduled during a treatment break to ensure adequate immune function and wound healing. Low platelet counts or suppressed white blood cell counts increase the risk of bleeding and infection during any surgical procedure.
Prior radiation: Patients who received radiation near the eye may have additional retinal or optic nerve damage that limits how much vision the cataract surgery can restore. The cataract may be just one layer of the visual problem.
Pediatric considerations: In young children, cataract removal presents unique challenges. A study of cataract surgery in retinoblastoma patients described a technique involving extracapsular cataract extraction with intraocular lens implantation, posterior capsulotomy, and anterior vitrectomy to address the high rate of posterior capsule opacification that occurs in young eyes.⁹ Children’s eyes are more prone to inflammation and scarring after surgery, so the surgical approach is more involved.

For adult patients who are in remission or have stable disease, there is generally no reason to delay cataract surgery if vision is significantly impaired. The artificial lens lasts a lifetime and does not need replacement. Most patients notice dramatically improved vision within days of the procedure.

What Newer Targeted Therapies Mean for Eye Risk

As cancer treatment has shifted toward targeted therapies and kinase inhibitors, patients and oncologists naturally wonder whether these newer drugs carry the same eye risks as traditional chemotherapy. The evidence so far is mixed but generally reassuring for cataracts specifically. A study of gefitinib, an epidermal growth factor receptor inhibitor used in lung cancer, reviewed ophthalmological data from over 600 patients across Phase I and Phase II clinical trials and found no evidence of any consistent or drug-related eye toxicity.¹⁰

That said, the landscape of targeted therapy is enormous and still evolving. Some newer agents do cause ocular side effects ranging from dry eyes to retinal toxicity, even if cataracts are not the primary concern. The clinical review calling for standardized screening protocols applies to these newer agents as well, reflecting a growing awareness that eye monitoring needs to keep pace with the expanding oncology drug pipeline.⁷

Separating Chemo Cataracts from Age-Related Lens Changes

One complication in understanding this topic is that cataracts are extremely common in the general population. By age 80, more than half of all people either have a cataract or have already had cataract surgery. So when a 65-year-old cancer survivor develops cataracts, it can be unclear whether the chemotherapy accelerated the process or whether the cataracts would have developed regardless.

A few clues point toward a treatment-related cause rather than normal aging. Posterior subcapsular cataracts are the hallmark of steroid and drug-induced lens damage, while age-related cataracts more often start as nuclear sclerosis in the center of the lens. Bilateral cataracts that appear simultaneously and symmetrically after treatment are more suspicious than the gradual asymmetric progression typical of aging. And cataracts appearing in someone under 50, especially a childhood cancer survivor in their twenties or thirties, are almost certainly treatment-related.

From a practical standpoint, the distinction matters less for treatment (surgery is surgery) than for awareness and timing. If your cataracts are treatment-related, they may progress faster than typical age-related cataracts, and you should be followed more closely. Your ophthalmologist should know your full cancer treatment history, including which drugs you received and whether radiation was directed anywhere near the head.

Protecting Your Eyes During and After Treatment

There is no proven way to completely prevent chemotherapy-related cataracts if you need the drugs that cause them. The treatment priority is always the cancer. But a few practical steps can reduce your overall lens risk and help catch problems early:

UV protection: Ultraviolet light exposure is a modifiable risk factor for cataracts in general. Wearing UV-blocking sunglasses consistently during and after treatment adds a small layer of protection to lenses that may already be under chemical stress.
Steroid awareness: If you’re on long-term corticosteroids as part of your cancer treatment or for managing graft-versus-host disease, ask your oncologist whether the dose or duration can be minimized. Even modest reductions in cumulative steroid exposure may matter, given that six months of use nearly doubled the cataract surgery risk in one large study.⁵
Proactive eye exams: Request a baseline dilated eye exam before starting treatment if possible, and schedule follow-ups annually for at least five years after completing high-risk regimens.
Treatment history documentation: Keep a record of every drug you received, including supportive medications like dexamethasone, and share it with any eye doctor you see. Ophthalmologists who don’t treat cancer patients routinely may not think to ask about chemotherapy history.

Smoking cessation also reduces general cataract risk, though no study has specifically examined its interaction with chemotherapy-related lens damage. The same goes for diabetes management, since poorly controlled blood sugar independently accelerates lens clouding. For cancer patients already carrying elevated risk from their treatment, controlling these additional factors makes sense even without chemo-specific data.

1
PubMed. Cataract induced by short-term administration of large doses of busulfan: a case report
2
PubMed Central. The Risk of Cataract among Survivors of Childhood and Adolescent Cancer: A Report from the Childhood Cancer Survivor Study
3
Current Opinion in Ophthalmology. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients
4
PubMed. Cataracts induced by intermittent Decadron used as an antiemetic
5
Nature. Risks of cataract surgery in solid and hematologic cancer survivors
6
PubMed Central. Ocular Late Effects in Childhood and Adolescent Cancer Survivors: A Report from the Childhood Cancer Survivor Study
7
Elsevier / European Journal of Cancer. Clinical and imaging strategies for the assessment of the ocular side effects of systemic targeted anti-cancer therapies
8
Investigative Ophthalmology & Visual Science. Results of Cataract Surgery in Cancer Patients Receiving Chemotherapy
9
JAMA Ophthalmology. Cataract Surgery and Intraocular Lens Implantation in Patients With Retinoblastoma
10
Eye. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials